NCT06657391 Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
| NCT ID | NCT06657391 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Rongrong Liu |
| Condition | Transfusion Dependent Thalassemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 396 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 396 participants in total. It began in 2024-10-01 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor transplantation in TM.The purpose of this clinical trial is to evaluate whether recombinant humanized anti-CD25 monoclonal antibody is effective in preventing GVHD and its safety after haploidentical/matched unrelated donor hematopoietic stem cell transplantation. The main questions it aims to answer are: * Does recombinant humanized anti-CD25 monoclonal antibody reduce the incidence of GVHD disease after haploidentical/matched unrelated donor hematopoietic stem cell transplantation? * What medical problems will participants experience when using the recombinant humanized anti-CD25 monoclonal antibody? What is the quality of life after 2 years follow-up? In this clinical trail, participants will be randomly assigned to the intervention group or the control group by researchers in a 2:1 ratio. The intervention group will be given recombinant humanized anti-CD25 monoclonal antibody (1mg/Kg) combined with the standard GVHD prophylaxis after transplantation, while the control group will only receive the standard GVHD prophylaxis. The incidence of GVHD after transplantation in the two groups will be observed. The main evaluation is the clinical efficacy of recombinant humanized anti-CD25 monoclonal antibody in preventing aGVHD.
Eligibility Criteria
Inclusion Criteria: * patients with transfusion-dependent thalassemia; * patients who are planning to receive matched unrelated donor hematopoietic stem cell transplantation (MUD-HSCT) or HLA haploidentical donor hematopoietic stem cell transplantation (HID-HSCT); * physical condition score (Lansky/Karnofsky score) ≥ 70%; * patients (or legal guardians) voluntarily participate in the study and sign the informed consent form Exclusion Criteria: * patients with HLA-matched hematopoietic stem cell donors and willing to receive HLA-matched hematopoietic stem cell transplantation; * patients with known infectious diseases such as hepatitis B, hepatitis C, AIDS, syphilis, human T-lymphotropic virus, etc.; * patients with serious active bacterial, viral, fungal, malaria or parasitic infections; * patients with autoimmune deficiency diseases; * patients with a history of malignant tumors or current malignant tumors; * patients with important organ diseases or abnormal laboratory tests, including but not limited to: 1) patients with cirrhosis, liver fibrosis or active hepatitis, and/or abnormal liver function tests (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN; alkaline phosphatase ≥2.5×ULN); 2) patients with heart disease, or left ventricular ejection fraction (LVEF) \<60%, or severe iron deposition in the heart; 3) kidney disease, or blood creatinine ≥1.5×ULN with creatinine clearance \<30% of normal level; 4) patients with endocrine dysfunction; * patients with uncorrected bleeding disease; * patients with severe mental illness (such as severe depression, schizophrenia, etc.) or cognitive dysfunction (dementia, delirium, etc.), which are unable to cooperate with the study; * peripheral blood white blood cell (WBC) count \<3×10\^9/L or platelet count \<100×10\^9/L; * patients having received thalidomide treatment within the past 3 months; * patients having received any type of gene and/or cell therapy in the past; * patients with severe allergies; * female patients who are pregnant, breastfeeding, or planning to become pregnant within 1 year of participating in this trial; * patients who are participating in other clinical trials; * other situations that are not suitable for participation in this clinical trial as assessed by the investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06657391 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 20 Years, studying Transfusion Dependent Thalassemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06657391 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06657391 currently recruiting?
Yes, NCT06657391 is actively recruiting participants. Contact the research team at liurongrong@stu.gxmu.edu.cn for enrollment information.
Where is the NCT06657391 trial being conducted?
This trial is being conducted at Maoming, China, Liuzhou, China, Nanning, China, Yulin, China and 1 additional location.
Who is sponsoring the NCT06657391 clinical trial?
NCT06657391 is sponsored by Rongrong Liu. The trial plans to enroll 396 participants.